Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play
This article was originally published in The Tan Sheet
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says
You may also be interested in...
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats
Through 30 years working in the pharmaceutical industry, George Quesnelle became a leading expert on the Rx-to-OTC switch process. At GlaxoSmithKline, he led the charge in switching Nicorette and NicoDerm CQ smoking cessation products, as well as alli for weight loss.
With its recent hiring push drawing attention, FDA is quietly undertaking another recruitment effort - filling advisory committee roster vacancies